Industrialization of AAV manufacturing with Xcite® transient and stable production platforms

Suparna has over 15 years of broad pharmaceutical and CDMO experience driving innovation, drug discovery, product and service development for CNS, oncology and cell and gene therapy. Suparna works closely with the commercial, innovation and operations teams to develop asset strategy, commercial offerings and capabilities to ensure meeting the changing landscape of cell and gene customer needs.

In her role, she supports sales and marketing teams for pipeline development and new business acquisition. Previously to this role, she was the Innovation and Commercialization Manager at Lonza, with a focus on driving development, prioritization and commercialization of their innovation portfolio.

Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology.

Dr. Peng Wang earned his doctorate in Chemical and Biomolecular Engineering from UCLA. After his postdoctoral training at Harvard University, he worked as Senior Research Scientist at MD Anderson Cancer Center. Before transitioning to Lonza Business Development as Associate Director, he worked as Associate Director in the R&D to develop viral vector platforms.